Business Description
uniQure NV
ISIN : NL0010696654
Description
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.44 | |||||
| Equity-to-Asset | 0.09 | |||||
| Debt-to-Equity | 1.21 | |||||
| Debt-to-EBITDA | -0.43 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.53 | |||||
| Beneish M-Score | 13.52 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -26.7 | |||||
| 3-Year EBITDA Growth Rate | -23 | |||||
| 3-Year EPS without NRI Growth Rate | -36.2 | |||||
| 3-Year FCF Growth Rate | 0.4 | |||||
| 3-Year Book Growth Rate | -7.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 26.03 | |||||
| Future 3-5Y Total Revenue Growth Rate | 79.89 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.37 | |||||
| 9-Day RSI | 73.61 | |||||
| 14-Day RSI | 74.93 | |||||
| 6-1 Month Momentum % | 30.25 | |||||
| 12-1 Month Momentum % | -12.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.51 | |||||
| Quick Ratio | 6.51 | |||||
| Cash Ratio | 6.11 | |||||
| Days Inventory | 156.63 | |||||
| Days Sales Outstanding | 75.91 | |||||
| Days Payable | 74.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.2 | |||||
| Shareholder Yield % | 2.96 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 7.15 | |||||
| Operating Margin % | -700.37 | |||||
| Net Margin % | -837.8 | |||||
| FCF Margin % | -671.79 | |||||
| ROE % | -154.29 | |||||
| ROA % | -31.1 | |||||
| ROIC % | -91.15 | |||||
| ROC (Joel Greenblatt) % | -278.84 | |||||
| ROCE % | -24.38 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 29.36 | |||||
| PB Ratio | 15.15 | |||||
| EV-to-EBIT | -2.83 | |||||
| EV-to-Forward-EBIT | -5.33 | |||||
| EV-to-EBITDA | -3.05 | |||||
| EV-to-Forward-EBITDA | -4.8 | |||||
| EV-to-Revenue | 16.86 | |||||
| EV-to-Forward-Revenue | 12.45 | |||||
| EV-to-FCF | -2.5 | |||||
| Price-to-Median-PS-Value | 1.14 | |||||
| Earnings Yield (Greenblatt) % | -35.34 | |||||
| FCF Yield % | -22.83 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
uniQure NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 26.337 | ||
| EPS (TTM) (€) | -4.552 | ||
| Beta | 1.21 | ||
| Volatility % | 90.71 | ||
| 14-Day RSI | 74.93 | ||
| 14-Day ATR (€) | 0.808168 | ||
| 20-Day SMA (€) | 9.80015 | ||
| 12-1 Month Momentum % | -12.89 | ||
| 52-Week Range (€) | 3.3 - 16.4 | ||
| Shares Outstanding (Mil) | 48.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
uniQure NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
uniQure NV Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
uniQure NV Frequently Asked Questions
What is uniQure NV(FRA:UQ1)'s stock price today?
The current price of FRA:UQ1 is €14.66. The 52 week high of FRA:UQ1 is €16.40 and 52 week low is €3.30.
When is next earnings date of uniQure NV(FRA:UQ1)?
The next earnings date of uniQure NV(FRA:UQ1) is 2025-02-28 Est..
Does uniQure NV(FRA:UQ1) pay dividends? If so, how much?
uniQure NV(FRA:UQ1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers